Edition:
United States

DexCom Inc (DXCM.OQ)

DXCM.OQ on NASDAQ Stock Exchange Global Select Market

72.78USD
17 Aug 2017
Change (% chg)

$-0.28 (-0.38%)
Prev Close
$73.06
Open
$72.97
Day's High
$73.67
Day's Low
$72.72
Volume
505,872
Avg. Vol
369,788
52-wk High
$96.27
52-wk Low
$57.85

DXCM.OQ

Chart for DXCM.OQ

About

Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The... (more)

Overall

Beta: 0.43
Market Cap(Mil.): $6,324.14
Shares Outstanding(Mil.): 86.56
Dividend: --
Yield (%): --

Financials

  DXCM.OQ Industry Sector
P/E (TTM): -- 31.80 32.84
EPS (TTM): -0.77 -- --
ROI: -13.69 13.83 14.86
ROE: -21.66 16.65 16.11

BRIEF-Dexcom Q2 revenue $170.6 mln; names new CFO

* Q2 revenue $170.6 million versus I/B/E/S view $166.3 million

Aug 01 2017

BRIEF-Dexcom announces FDA approval of G5 mobile app for android devices

* Dexcom announces fda approval of g5 mobile app for android devices

Jun 07 2017

BRIEF-Dexcom prices offering of $350 mln of 0.75% convertible senior notes

* Prices offering of $350 million of 0.75% convertible senior notes

May 08 2017

BRIEF-Dexcom announces proposed offering of convertible senior notes

* Dexcom announces proposed offering of $300 million of convertible senior notes

May 08 2017

BRIEF-DexCom appoints Richard Collins to board of directors

* DexCom appoints Richard Collins to board of directors Source text for Eikon: Further company coverage:

Mar 13 2017

BRIEF-Dexcom Inc says committed to borrow $75 mln in principal amount under its existing $200 mln revolving credit facility - SEC filing

* Dexcom Inc - on February 28, 2017, co committed to borrow $75 million in principal amount under its existing $200 million revolving credit facility - SEC filing

Mar 06 2017

BRIEF-Dexcom Q4 gaap loss per share $0.09

* Dexcom, inc. Reports fourth quarter and fiscal year 2016 financial results

Feb 28 2017

BRIEF-Dexcom says chief financial officer to resign, effective as of April 1

* Dexcom Inc- on Feb 14 Jess Roper, chief financial officer notified Dexcom of his decision to resign, effective as of April 1, 2017 - sec filing

Feb 21 2017

Competitors

  Price Chg
Roche Holding Ltd. (ROG.S) CHF244.20 --
Roche Holding Ltd. (RO.S) CHF246.80 --
Johnson & Johnson (JNJ.N) $133.04 -1.13
Abbott Laboratories (ABT.N) $49.29 -0.52
Medtronic PLC (MDT.N) $83.67 -0.93

Earnings vs. Estimates